Brendan Manning joined the AI Therapeutics Scientific Advisory Board in May, 2013. Dr. Manning is a Professor in the Department of Genetics and Complex Diseases at the Harvard School of Public Health (HSPH). His doctoral training was in the laboratory of Michael Snyder at Yale University, where he worked basic mechanisms of cell division. Following receipt of his Ph.D. in 2000, Dr. Manning joined the laboratory of Lewis Cantley at Harvard Medical School for his postdoctoral research. During this time, he identified the tuberous sclerosis complex (TSC) tumor suppressor as the molecular connection between the PI3K and mTOR pathways, thereby linking a signaling pathway activated in the majority of human cancers to a nutrient-sensing pathway that controls cell growth and metabolism. In 2004, Dr. Manning joined the faculty of the then newly established Department of Genetics and Complex Diseases at HSPH to continue research at the interface of cancer and metabolism. He serves on multiple editorial boards, the Scientific Advisory Board of the LAM Foundation, and the Science and Medical Committee of the Tuberous Sclerosis Alliance.